Sintana Energy Inc (TSX-V:SEI, OTCQB:SEUSF) has snapped up a stake in some the of last remaining acreage in Namibia’s Orange basin hotspot, acquiring a material interest in the PEL 79 licence block located to the east of the ‘world-class’ Mopane discovery.
The Canadian exploration company holds around 5% of Galp-operated Mopane, which was confirmed as a significant commercial discovery by the Portuguese firm earlier this week.
AIM-listed battery technology company Ilika PLC (AIM:IKA, OTCQX:ILIKF)’s “very upbeat” capital markets day, to use broker Liberum’s words, has been met with a solid reaction, with shares sent 8% higher on Wednesday.
Ilika outlined “impressive operational progression” over the past 12 months, said analysts, with financial reports setting the stage for a “robust liquidity position” in the year ahead.
ANGLE PLC (AIM:AGL, OTCQX:ANPCY) shares jumped 30% following the announcement of a strategic partnership with AstraZeneca PLC (LSE:AZN) that aims to advance cancer drug development by enhancing the former's DNA damage response assay.
Specifically, the collaboration will focus on adapting ANGLE's existing Parsortix-based assay for identifying micronuclei in circulating tumour cells (CTCs), a crucial step in studying DNA damage responses.
88 Energy Ltd (AIM:88E, ASX:88E, OTC:EEENF) told investors it has successfully completed the bookbuild for its placing, raising £5.23 million (A$9.9 million) of new equity.
The junior oil and gas company, in a statement, said it will issue 3.29 billion new shares priced at A$0.003 each.
Atlantic Lithium Ltd (AIM:ALL, OTCQX:ALLIF, ASX:A11) said the chief focus of the past quarter was to continue de-risking the Ewoyaa lithium project in Ghana to enable it to break ground later this year.
"Key to achieving this milestone is the success of the ongoing permitting process, which is advancing as anticipated,” said executive chairman Neil Herbert in a quarterly update.
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the developer of liquid biopsy technologies, has partnered with AstraZeneca PLC (LSE:AZN) to enhance cancer drug development by 'leveraging' the former's DNA damage response assay.
Specifically, the collaboration will focus on adapting ANGLE's existing Parsortix-based assay for identifying micronuclei in circulating tumour cells (CTCs), a crucial step in studying DNA damage responses.